Featured

Cytokine-armed DC progenitors are an alternative to antigen-loaded DC vaccines

Using tumor antigen-loaded monocyte-derived DCs for therapeutic vaccination is a strategy that has been well explored, but with mixed clinical results. While this strategy can be effective, it is limited by the requirement for accessible tumor...

Read More

In the Spotlight...

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells

The anaplastic lymphoma kinase (ALK) receptor is an oncogenic driver specifically expressed by neuroblastoma. Bergaggio, Tai, et al. developed CAR-T recognizing the ALK extracellular domain. In mouse ...

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

Larson et al. generated CAR T cells specific for TACI, which, unlike BCMA, showed negligible RNA expression in the basal ganglia. Anti-TACI-CAR T cells were cytotoxic against TACI+ targets in vitro a...

PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models

Wong et al. demonstrated that chronic IFNγ exposure upregulated the IFNγ target gene product poly-ADP ribosyl polymerase 14 (PARP14) via the IFNγ-STAT1 axis, and drove resistance to anti-PD-1 therapy....

Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers

Yossef et al. demonstrated that neoantigen-specific CD8+ T cells from circulating blood of patients with metastatic cancer exhibited a distinct transcriptional state that was shared among patients and...
See all for this week

Previous Digests

Activating macrophages to remodel the tumor microenvironment

November 29, 2023

One of the reasons immune checkpoint blockade (ICB) may fail in solid tumors like pancreatic ductal adenocarcinoma (PDA) is a lack of T cell infiltration and extensive myeloid inflammation in the tumor microenvironment (TME). Wattenberg et al. aimed to...

Metabolic characteristics of DC vaccines define therapy responses

November 22, 2023

Dendritic cell (DC)-based cancer vaccines have great potential but are currently lacking in efficacy. Adamik et al. investigated the transcriptomic and immune-metabolic characteristics of DCs from patients with melanoma to better understand how cancer may impact antigen presentation function...

SITC - 38th Annual Meeting 2023

November 15, 2023

This week’s extensive special feature covers select talks from the SITC - 38th Annual Meeting 2023 in San Diego, CA. We have organized the content by topics below. Keynote AddressSusan Kaech Microbiome and metabolismSusan BullmanYoungseok ChoLydia Lynch Cell-based immunotherapiesFelix...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Samuel (Sandy) Goldman

Samuel (Sandy) Goldman

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Elaine Yee Lin Chung

Elaine Yee Lin Chung

Nathan Suek

Nathan Suek

Margot O'Toole

Margot O'Toole

More About Us

TESTIMONIALS

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

 — Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Testimonials

Current Sponsors

Past Sponsors
Close Modal

Subscribe to our mailing list

GDPR Marketing Permissions

The Fritsch Foundation/ACIR.org will use the information you provide on this form to be in touch with you and to send you a weekly digest on cance immunotherapy. Click below to confirm that you want to receive the weekly digest by:

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at contact@acir.org. We will treat your information with respect and will never share it with any third-parties. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.